The United States Food and Drug Administration (FDA) has approved different drugs designed against the different mutant genes in NSCLC For example, erlotinib, gefitinib, afatinib and osimertinib were developed to target EGFR (discussed later in this review); crizotininb, ceritinib, alectinib and brigatinib were developed to target ALK (crizotinib also targets ROS1). Here, EGFR is linked to non-small cell lung carcinoma.